CL
RLMD icon

CSS LLC’s Relmada Therapeutics RLMD Stock Holding History

CSS LLC’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,900
Closed -$663K – 1078
2022
Q3 		$663K Buy
+17,900
New +$496K 0.03% 445
2021
Q4 		– Sell
-8,400
Closed -$220K – 1314
2021
Q3 		$220K Buy
+8,400
New +$225K 0.01% 851

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's RLMD Position: Q4 2022 in Review

CSS LLC sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 2,253 shares — an estimated $19.8K sold.

CSS LLC first reported a position in RLMD in Q3 2021 and held it in 5 quarters. The position peaked at $605K in Q1 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • CSS LLC reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CSS LLC sold 2,253 Relmada Therapeutics shares in Q4 2022, an estimated $19.8K.
  • CSS LLC first reported a position in Relmada Therapeutics in Q3 2021 and held it in 5 quarters.
  • CSS LLC's Relmada Therapeutics position peaked at $605K in Q1 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.